pathfndr header uai

This webinar is intended for Medical Professionals only

Join Peter Trainer, MD, David Clemmons MD, and other experts from Crinetics Pharmaceuticals for a 30-minute webinar on paltusotine, an investigational treatment for acromegaly.

Also learn about the Phase 3 PATHFNDR trials for paltusotine now underway.

Our drug candidate, paltusotine, is a ONCE DAILY, ORAL treatment. If approved, it would establish a new class of oral, selective, nonpeptide, somatostatin receptor type 2 (SST2) agonists designed for the treatment of acromegaly. Our Phase 3 trials are now underway and enrolling participants, so please join us to learn more.

Advancing Acromegaly Treatment Webinar
for Medical Professionals

Tuesday, June 7
3:00pm PDT, 6:00pm EDT

Register Now

Wednesday, June 8
8:00am PDT, 11:00am EDT

Register Now


  • The need for new acromegaly therapies
  • Overview of investigational paltusotine
  • PATHFNDR studies and Phase 2/OLE interim findings
  • Q&A with Crinetics leaders

This webinar is intended for Medical Professionals only


peter trainer, md, frscp, vp, clinical endocrinology

Peter Trainer, MD, FRSCP
VP, Clinical Endocrinology

david clemmons, md, scientific advisor

David Clemmons, MD
Scientific Advisor

alessandra casagrande, md, phd, medical sciences director

Alessandra Casagrande, MD, PhD
Medical Sciences Director

alan krasner, md, chief medical officer

Alan S. Krasner, MD
Chief Medical Officer

Now Recruiting for Phase 3

The PATHFNDR studies are now underway and recruiting participants. These Phase 3, randomized, placebo-controlled, multi-center studies are evaluating the safety and efficacy of paltusotine, an investigational treatment for patients with acromegaly. Paltusotine was shown in Phase 2 studies to maintain IGF-1 levels in patients with acromegaly who were previously on octreotide LAR or lanreotide depot monotherapy.

Click below for key study eligibility/exclusion criteria and additional information.

Learn More

If you have patients with acromegaly who might consider participating in the PATHFNDR studies, click here for information about how to refer patients to study sites.